Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Linda Santiago"'
Autor:
Linda Santiago, Jane Carter, Ashok Bandaranayake, Colin Correnti, Ida Lin, Man Kid Chan, Scott Delbecq, Midori Clarke, Eric Gruff, William Bracken, David Meininger, Diana Hausman, Christopher Mehlin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0d3920428a8642d09c60be88e0f59db9
Autor:
Raj Tummala, Shiliang Wang, Lorin Roskos, Bing Wang, Linda Santiago, Denison Kuruvilla, Yen Lin Chia
Publikováno v:
Rheumatology. 60:5854-5862
Objectives The randomized, double-blind, phase 2 b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300 mg or 1000 mg every 4 weeks) compared with placebo for 52 weeks in patients with chronic, moderate to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962edd9d56d3ed2cd033aae87af98080
https://doi.org/10.1093/rheumatology/keab176
https://doi.org/10.1093/rheumatology/keab176
Autor:
Melissa Lynne Johnson, Grace K. Dy, Hirva Mamdani, Afshin Dowlati, Adam Jacob Schoenfeld, Jose Maria Pacheco, Rachel E. Sanborn, Smitha Patiyil Menon, Linda Santiago, Yifah Yaron, Himisha Beltran
Publikováno v:
Journal of Clinical Oncology. 40:8566-8566
8566 Background: HPN328 is a delta like canonical Notch ligand 3 (DLL3)-targeting T-cell engager (TCE) derived from the TriTAC platform, designed to minimize off-target toxicities. HPN328 contains 3 binding domains, engineered to redirect T cells to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b466d4fd30707ad081034e31174b4b0d
https://doi.org/10.1200/jco.2022.40.16_suppl.8566
https://doi.org/10.1200/jco.2022.40.16_suppl.8566
Autor:
Mary Tagliaferri, Michiel S. van der Heijden, Robert Huddart, Mehmet Asim Bilen, Bob Zhong, Vadim S. Koshkin, Aristotelis Bamias, Linda Santiago, Maged F. Khalil, Mustafa Ozguroglu, Thomas Powles, Arjun Vasant Balar, Arlene O. Siefker-Radtke, Wei Lin, Yohann Loriot, David Chien, Daniel Castellano, David Pook
MUSTAFA, OZGUROGLU/0000-0002-8417-8628; huddart, robert/0000-0003-3604-1990; Balar, Arjun/0000-0003-3949-5656 WOS:000570162100001 PubMed ID: 32938232 The choice of first-line therapy for patients with metastatic urothelial cancer (mUC) is based on ci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc6ad0001a7eaa2cf95a9029c3cb32c
https://doi.org/10.2217/fon-2020-0795
https://doi.org/10.2217/fon-2020-0795
Autor:
Maryalice Stetler-Stevenson, Mark C. Lanasa, Tadeusz Robak, David J. FitzGerald, Robert J. Kreitman, Linda Santiago, Martin S. Tallman, Wyndham H. Wilson, Guozhi Gao, Steven Coutre, Ira Pastan
Publikováno v:
Blood. 131:2331-2334
Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL; n = 28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39028ead54b31fa183cd83d8a699bfe6
https://doi.org/10.1182/blood-2017-09-803072
https://doi.org/10.1182/blood-2017-09-803072
Autor:
Aristotelis Bamias, Mehmet Asim Bilen, Linda Santiago, Yohann Loriot, Arlene O. Siefker-Radtke, Mustafa Ozguroglu, Pao-Chen Li, Mary Tagliaferri, Margit Cecile Tagliaferri, Thomas Powles, Michiel S. van der Heijden, Rabih Saab, Daniel Castellano, David Pook, Maged F. Khalil, Robert Huddart, Arjun Vasant Balar, Vadim S. Koshkin, Wei Lin
Publikováno v:
Publons
TPS589 Background: Checkpoint inhibitors can achieve durable responses in cis-ineligible 1L mUC. However, use is restricted to patients whose tumors are PD-L1 high. Approximately 70% of cis-ineligible patients have tumors with low PD-L1 expression, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1f6474474a866605a7534ae64e40f6
https://doi.org/10.1200/jco.2020.38.6_suppl.tps589
https://doi.org/10.1200/jco.2020.38.6_suppl.tps589
Publikováno v:
Poster Presentations.
Background Anifrolumab is a fully human anti–interferon-α receptor monoclonal antibody in Phase III development for systemic lupus erythematosus (SLE). In Phase IIb trials, intravenous (IV) anifrolumab (300 mg every 4 weeks) significantly decrease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb88d2e2f1d4e85f2a9b16e07e4855a5
https://doi.org/10.1136/annrheumdis-2017-eular.2149
https://doi.org/10.1136/annrheumdis-2017-eular.2149
Autor:
Robert J. Kreitman, Chih-Ming Tseng, Kemal Balic, Meina Liang, Linda Santiago, Nathan Standifer, Denison Kuruvilla, Nai-Shun Yao, Ira Pastan, Xia Li, Raffaella Faggioni, Lorin Roskos, Inna Vainshtein
Publikováno v:
Journal of Clinical Oncology. 36:7061-7061
7061Background: Moxe is a recombinant immunotoxin that specifically binds to CD22 on the B cell surface and internalizes leading to cell death. The PK, PD, and immunogenicity of moxe were evaluated...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5260e35518278dcdcec4443852b67c0
https://doi.org/10.1200/jco.2018.36.15_suppl.7061
https://doi.org/10.1200/jco.2018.36.15_suppl.7061
Autor:
Chih-Ming Tseng, Meina Liang, Ira Pastan, Xia Li, Nai-Shun Yao, Lorin Roskos, Kemal Balic, Robert J. Kreitman, Linda Santiago, Denison Kuruvilla, Raffaella Faggioni, Yen Lin Chia
Publikováno v:
Journal of Clinical Oncology. 36:7060-7060
7060Background: Moxe is an immunotoxin targeting CD22 on B cells leading to cell death. The objectives of this analysis were to characterize the pharmacokinetics (PK) and evaluate the exposure-effi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68edf23315e9751c72048fbfda00af01
https://doi.org/10.1200/jco.2018.36.15_suppl.7060
https://doi.org/10.1200/jco.2018.36.15_suppl.7060
Publikováno v:
Lupus Science & Medicine
Objectives To compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor monoclonal antibody in development for SLE, in healthy volunteers. Methods In this Phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ba30ddb899c2bdf3b5c57c633bd4e2
https://doi.org/10.1136/lupus-2017-000252
https://doi.org/10.1136/lupus-2017-000252